<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766840</url>
  </required_header>
  <id_info>
    <org_study_id>YMCART202005</org_study_id>
    <nct_id>NCT04766840</nct_id>
  </id_info>
  <brief_title>Donor-derived CAR-T Cells in the Treatment of AML Patients</brief_title>
  <official_title>A Study to Evaluate the Safety and Efficacy of Donor-derived CAR-T Cells in the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study to evaluate the safety and efficacy of donor-derived CAR-T cells in&#xD;
      the treatment of patients with relapsed or refractory acute myeloid leukemia in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, single-arm, open-label study. This study is planned to enroll about&#xD;
      9 subjects with relapsed or refractory acute myelogenous leukemia and 9 matched donors for&#xD;
      leukapheresis and CAR-T cells manufacture. Donor-derived CAR-T cells were then infused&#xD;
      intravenously into subjects, in a dose-escalating 3+3 design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>28 days</time_frame>
    <description>≥ Grade 4 adverse event related to CAR-T cells infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>28 days</time_frame>
    <description>Patients who achieve CR（complete response） or CRi 28 days after CAR-T cells infusuion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>IM73 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: IM73 CAR-T Cells&#xD;
Fludarabine&#xD;
Cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAR-T cells</intervention_name>
    <description>Drug: IM73 CAR-T Cells Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days</description>
    <arm_group_label>IM73 CAR-T</arm_group_label>
    <other_name>IM73 CAR-T Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractory or relapsed AML patients.&#xD;
&#xD;
          -  Have found an appropriate matched donor for CAR-T cells manufacturing.&#xD;
&#xD;
          -  Patients must have evaluable evidence of disease.&#xD;
&#xD;
          -  Age ≥ 18 years; Expected survival is more than 3 months.&#xD;
&#xD;
          -  ECOG score 0-2 points.&#xD;
&#xD;
          -  Women of childbearing age have negative blood pregnancy test before the start of the&#xD;
             trial, and agree to take effective contraceptive measures during the trial until the&#xD;
             last follow-up; male subjects with partners of childbearing potential agree to take&#xD;
             effective contraceptive measures during the trial until the last follow-up.&#xD;
&#xD;
          -  Adequet liver, kidney, heart and lung function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed acute promyelocytic leukemia; or recent symptomatic central nervous system&#xD;
             leukemia.&#xD;
&#xD;
          -  Patients with graft-versus-host disease requiring the use of immunosuppressive agents;&#xD;
             or patients with autoimmune system diseases.&#xD;
&#xD;
          -  Prior use of any gene therapy product.&#xD;
&#xD;
          -  History of epilepsy or other central nervous system diseases.&#xD;
&#xD;
          -  Presence of concurrent active malignancy.&#xD;
&#xD;
          -  Active hepatitis B or C virus, patients with HIV or syphilis infection.&#xD;
&#xD;
          -  Currently participating in or having participated in other drug clinical trials during&#xD;
             past 30 days.&#xD;
&#xD;
          -  Active or uncontrolled infection requiring systemic therapy within 14 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Other situations not suitable for the study judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>FEI Wu</last_name>
    <phone>15801390058</phone>
    <email>wufei@immunochina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaojun Huang, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital (PKUPH)</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR-T</keyword>
  <keyword>Immunotherapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

